

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 471/04, A61K 31/505 // (C07D 471/04, 239:00, 221:00)		A1	(11) International Publication Number: WO 96/28444
			(43) International Publication Date: 19 September 1996 (19.09.96)
(21) International Application Number: PCT/IB95/00172		(81) Designated States: CA, FI, JP, MX, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 15 March 1995 (15.03.95)			
(71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).		Published With international search report.	
(72) Inventor; and (75) Inventor/Applicant (for US only): DOW, Robert, L. [US/US]; 132 Shore Road, Waterford, CT 06385 (US).			
(74) Agents: SPIEGEL, Allen, J. et al. ; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).			
(54) Title: 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS			

(57) Abstract

Certain 5,10-dihydropyrimido[4,5-b]quinolin-4(1H)-one compounds of formula (I), and their pharmaceutically acceptable salts, useful as inhibitors of tyrosine kinase enzymes and for the treatment of tyrosine kinase dependent diseases (e.g., cancer, atherosclerosis, antiangiogenesis).



(I)

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE
TYROSINE KINASE INHIBITORS

This invention relates to 5,10-dihydropyrimido-[4,5-b]quinolin-4(1H)-one compounds which are tyrosine kinase inhibitors, pharmaceutical compositions containing such tyrosine kinase inhibitors, and the use of such tyrosine kinase inhibitors to treat tyrosine kinase dependent diseases such as cancer, antiangiogenesis and atherosclerosis, in mammals.

Background of the Invention


Tyrosine-specific protein kinases (tyrosine kinases) represent a family of enzymes which catalyze the transfer of the terminal phosphate of adenosine triphosphate to tyrosine residues in protein substrates. The first members of this class to be identified were tyrosine kinases associated with viral genes (termed oncogenes) which were capable of cell transformation (i.e. pp60v-src and pp98v-fps). Later it was shown that there were normal cellular counterparts (i.e. pp60c-src and pp98c-fps) to these viral gene products. A third category of tyrosine kinases to be identified are those termed the growth factor receptors, which includes insulin, epidermal growth factors, and p185HER-2 receptors. All of these tyrosine kinases are believed, by way of substrate phosphorylation, to play critical roles in signal transduction for a number of cell functions.

Though the exact mechanisms of signal transduction have yet to be elucidated, tyrosine kinases have been shown to be important contributing factors in cell proliferation, carcinogenesis and cell differentiation. Therefore, inhibitors of these tyrosine kinases are useful for the prevention and chemotherapy of proliferative diseases dependent on these enzymes.

Summary of the Invention

This invention is directed to 5,10-dihydropyrimido[4,5-b]quinolin-4(1H)-one compounds that are useful as tyrosine kinase inhibitors. The compounds of this invention have Formula I

-2-



5

Formula I

or their pharmaceutically acceptable salts and prodrugs thereof, wherein

R_1 is H, alkyl(C_1-C_4), formylalkyl(C_1-C_4), alkyl(C_1-C_4)carbonylalkyl(C_1-C_4),
 10 carboxyalkyl(C_1-C_4), alkoxy(C_1-C_4)carbonylalkyl(C_1-C_4), carbamoylalkyl(C_1-C_4), mono-N-
 or di-N,N-alkyl(C_1-C_4)aminocarbonylalkyl(C_1-C_4), formylcarbamoylalkyl(C_1-C_4),
 alkanoyl(C_1-C_4)carbamoylalkyl(C_1-C_4), alkoxy(C_1-C_4)carbonylcarbamoylalkyl(C_1-C_4),
 morpholinocarbonylalkyl(C_1-C_4), 1-pyrrolidinylcarbonylalkyl(C_1-C_4), 1-
 piperidinylcarbonylalkyl(C_1-C_4), 4-thiomorpholinylcarbonylalkyl(C_1-C_4), 1-
 15 piperazinylcarbonylalkyl(C_1-C_4), 4-alkyl(C_1-C_4)-1-piperazinylcarbonylalkyl(C_1-C_4),
 hydroxyalkyl(C_1-C_4), alkoxy(C_1-C_4)alkyl(C_1-C_4), mono-N- or di-N,N-alkyl(C_1-C_4)
 aminoalkyl(C_1-C_4), aminoalkyl(C_1-C_4), formylaminoalkyl(C_1-C_4), alkanoyl(C_1-C_4)
 aminoalkyl(C_1-C_4), alkoxy(C_1-C_4)carbonylaminoalkyl(C_1-C_4), 1-pyrrolidinylalkyl(C_1-C_4),
 1-piperidinylalkyl(C_1-C_4), 4-thiomorpholinylalkyl(C_1-C_4), morpholinoalkyl(C_1-C_4), 1-
 20 piperazinylalkyl(C_1-C_4) or 4-alkyl(C_1-C_4)-1-piperazinylalkyl(C_1-C_4);

R_2 is formyl, alkyl(C_1-C_4)carbonyl, carboxy, alkoxy(C_1-C_4)carbonyl, carbamoyl,
 mono-N- or di-N,N-alkyl(C_1-C_4)aminocarbonyl, formylcarbamoyl, alkanoyl(C_1-C_4)
 carbamoyl, alkoxy(C_1-C_4)carbonylcarbamoyl, morpholinocarbonyl,
 morpholinoalkyl(C_1-C_4)carbamoyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, 4-
 25 thiomorpholinylcarbonyl, 1-piperazinylcarbonyl or 4-alkyl(C_1-C_4)-1-piperazinylcarbonyl
 or such R_2 groups substituted on alkyl(C_1-C_4), or R_2 is H, alkyl(C_1-C_4), hydroxyalkyl(C_1-C_4),
 alkoxy(C_1-C_4)alkyl(C_1-C_4), mono-N- or di-N,N-alkyl(C_1-C_4)aminoalkyl(C_1-C_4),
 aminoalkyl(C_1-C_4), formylaminoalkyl(C_1-C_4), alkanoyl(C_1-C_4)aminoalkyl(C_1-C_4), alkoxy(C_1-C_4)
 carbonylaminoalkyl(C_1-C_4), 1-pyrrolidinylalkyl(C_1-C_4), 1-piperidinylalkyl(C_1-C_4), 4-
 30 thiomorpholinylalkyl(C_1-C_4), morpholinoalkyl(C_1-C_4), 1-piperazinylalkyl(C_1-C_4) or 4-
 alkyl(C_1-C_4)-1-piperazinylalkyl(C_1-C_4); and

R_3 and R_4 are each independently H, alkyl(C_1-C_4), perhaloalkyl(C_1-C_4),
 methoxyphenylthio, alkoxy(C_1-C_6), perhaloalkoxy(C_1-C_6), formyl, alkyl(C_1-C_4)carbonyl,

carboxy, alkoxy(C₁-C₄)carbonyl, carbamoyl, mono-N- or di-N,N- alkyl(C₁-C₄)aminocarbonyl, formylcarbamoyl, alkanoyl(C₁-C₄)carbamoyl, alkoxy(C₁-C₄)carbonylcarbamoyl, morpholinocarbonyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, 4-thiomorpholinylcarbonyl, 1-piperazinylcarbonyl, 4-alkyl(C₁-C₄)-1-piperazinylcarbonyl, mono-N- or di-N,N-alkyl(C₁-C₄)amino, amino, formylamino, alkanoyl(C₁-C₄)amino, alkoxy(C₁-C₄)carbonylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-thiomorpholinyl, morpholino, 1-piperazinyl or 4-alkyl(C₁-C₄)-1-piperazinyl;

with the proviso that R₁, R₂, R₃ and R₄ are not all H.

A first group of preferred compounds of Formula I are those compounds

10 wherein

R₁ is H, methyl or morpholinopropyl;

R₂ is H or morpholinopropylcarbamoyl;

R₃ is 7-methoxy; and

R₄ is 8-methoxy.

15 A second group of preferred compounds of Formula I are those compounds wherein

R₁ is H;

R₂ is alkyl(C₁-C₄);

R₃ is H or 7-methoxy; and

20 R₄ is H or 8-methoxy.

A third group of preferred compounds of Formula I are those compounds wherein R₁ and R₂ are H; and R₃ and R₄ are each independently alkoxy(C₁-C₄).

Within this third group of preferred compounds of Formula I is a first group of especially preferred compounds wherein R₃ is 7-alkoxy(C₁-C₄) and R₄ is 8-alkoxy(C₁-C₄).

25 Within the third group of preferred compounds of Formula I is a second group of especially preferred compounds wherein R₃ and R₄ are each independently methoxy.

Particularly preferred compounds within the above second group of especially preferred compounds are compounds wherein R₃ is 6-methoxy or 8-methoxy and R₄ is 9-methoxy.

30 A fourth group of preferred compounds of Formula I are those compounds wherein R₃ is H; and R₄ is alkoxy(C₁-C₄).

Within this fourth group of preferred compounds of Formula I is a first group of especially preferred compounds wherein R_1 and R_2 are H; and R_4 is 7-methoxy or 8-methoxy.

A particularly preferred compound of Formula I is a compound wherein R_1 , R_2 and R_3 are H; and R_4 is 7-((4-methoxyphenyl)thio).

The present invention is also directed to pharmaceutical compositions which comprise a therapeutically effective amount of a compound of Formula I and a pharmaceutically-acceptable carrier.

Yet another aspect of this invention is a method of treating tyrosine kinase dependent diseases which comprises administering to a mammal suffering from a tyrosine kinase dependent disease a tyrosine kinase dependent disease treating amount of a compound of Formula I.

By halo is meant chloro, bromo, iodo, or fluoro.

By alkyl is meant straight chain or branched saturated hydrocarbon.

The expression "pharmaceutically-acceptable salts" refers to nontoxic cationic salts such as (but not limited to) sodium, potassium, calcium, magnesium, ammonium or protonated benzathine (N,N'-dibenzylethylenediamine), choline, ethanolamine, diethanolamine, ethylenediamine, meglamine (N-methyl-glucamine), benethamine (N-benzylphenethylamine), piperazine or tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) and nontoxic anionic salts such as (but not limited to) chloride, bromide, iodide, sulfate, bisulfate, phosphate, acetate, maleate, fumarate, oxalate, lactate, tartrate, citrate, gluconate and 4-toluene-sulfonate.

The expression "prodrug" refers to compounds that are drug precursors, which following administration and absorption, release the drug *in vivo* via some metabolic process. Exemplary prodrugs upon cleavage release the corresponding free acid, and such hydrolyzable ester residues of the Formula I compounds include but are not limited to substituents wherein the R_1 , R_2 , R_3 , or R_4 substituents contain carboxyl in which the free hydrogen is replaced by (C₁-C₄)alkyl, (C₂-C₇)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-

(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C₁-C₂)alkylamino(C₂-C₃)alkyl (such as β -dimethylaminoethyl), carbamoyl-(C₁-C₂)alkyl, N,N-di(C₁-C₂)alkylcarbamoyl-(C₁-C₂)alkyl and piperidino-, pyrrolidino- or morpholino(C₂-C₃)alkyl. In addition, other
5 exemplary prodrugs are those that upon cleavage release the corresponding free amine. Such hydrolyzable amide or imide residues of the Formula I compounds include, but are not limited to, substituents wherein R₁, R₂, R₃, or R₄ substituents contain amines in which the free hydrogen is replaced by a variety of acyl moieties.


As used herein, the expression "reaction-inert solvent" refers to a solvent which
10 does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.

One of ordinary skill will recognize that certain substituents detailed in this invention will be chemically incompatible with one another or with the heteroatoms in the compounds, and will avoid these incompatibilities in selecting compounds of this
15 invention.

Other features and advantages will be apparent from the specification and claims.

Detailed Description of the Invention

REACTION SCHEME I



According to Reaction Scheme I the Formula I compounds wherein R_1 , R_2 , R_3 and R_4 are as defined above, with the proviso that R_1 is not H (i.e., Formula XII compounds), may be prepared from the appropriate Formula XIII compounds, wherein R_2 , R_3 and R_4 are as defined above, by alkylation.

- 5 Typically the Formula XIII compounds are heated at 50°C to 150°C in a polar solvent such as an aqueous solvent for about 0.5 to 3 hours with the appropriate alkyl halide, sulfonate, or sulfate in the presence of a hydroxide base such as sodium or potassium hydroxide.

- 10 The Formula I compounds wherein R_3 and R_4 are as defined above, with the proviso that when R_2 is H, R_1 is as defined above and when R_1 is H, R_2 is as defined above (i.e., Formula III and XIII compounds) may be prepared by reduction of the appropriate Formula IV, V and XIV compounds wherein R_1 , R_3 , R_4 are as defined above and R_5 is as defined for R_2 above.

- 15 Typically the Formula IV, V and XIV compounds are reduced for example, by hydrogenation (e.g., ammonium formate or hydrogen in the presence of a catalyst), in a polar, high boiling solvent such as formamide, dimethylformamide (DMF) or dimethylsulfoxide (DMSO). The reaction is carried out at elevated temperatures of about 100°C to 250°C and pressures of ambient to 100 psi for a period of three to twenty-four hours. Conveniently, pressures of 30 to 100 psi are used for catalytic
20 hydrogenation. Generally an excess of the hydrogen donating species is used and, preferably greater than ten equivalents of the hydrogen donating species is used. Preferably the hydrogen donating species is added portionwise over the course of the reaction when ammonium formate is used.

- 25 The Formula IV compounds wherein R_3 and R_4 are as defined above may be prepared from the appropriate Formula XIV compounds wherein R_3 and R_4 are as defined above and R_5 is an ester that contains a group that is easily displaced (e.g., alkoxy) by condensation with the appropriate amine to produce the desired amide. Generally, the appropriate Formula XIV compound is heated at about 100°C to 200°C for about one to three hours in a polar high boiling solvent such as DMSO or DMF with
30 the appropriate amine.

Formula XIV compounds wherein R_3 and R_4 are as defined above, and R_5 is as defined for R_2 above (and in addition may be an ester), may be prepared from the appropriate Formula VII compounds, wherein R_3 and R_4 are as defined above and X is

either an ester (that contains an easily displaceable leaving group e.g., alkoxy) or a carbamoyl moiety, by cyclization with an alkyl oxalate compound or a compound of the formula $R_5C(O)NH_2$ or $R_5C(OR)_3$, wherein R_5 is as defined above and OR is an easily displaceable leaving group.

5 Generally the Formula VII compounds are heated neat at 150°C to 250°C for about four to twenty-four hours with the appropriate amide or ortho ester. For the case of an orthoester an acid catalyst such as a sulfonic acid or mineral acid is employed.

 The Formula VII compounds wherein R_3 , R_4 and X are as defined above may be prepared by the procedures described in Campaigne, E; Randau, G., J. Het. Chem.
10 1971, 8, 111 and as follows hereinafter.

 The Formula VII compounds wherein R_3 , R_4 and X are as defined above may be prepared from the appropriate Formula VIII compounds, wherein R_3 , R_4 and X are as defined above, by reduction. Generally, the Formula VIII compounds are reduced by exposure to a reducing agent (e.g., iron or zinc) in a weak, solubilizing acid such as
15 acetic acid at elevated temperatures of about 50°C to 150°C.

 The Formula VIII compounds wherein R_3 , R_4 and X are as defined above, may be prepared from the appropriate Formula IX compounds wherein R_3 and R_4 are as defined above by condensation with the appropriate Formula X compound wherein X is as defined above. Typically the Formula IX compounds are reacted with Formula X
20 compounds in the presence of an amine base (e.g., piperidine, pyrrolidine, etc.) in an alcoholic solvent (MeOH, EtOH, etc.) at a temperature of about 50°C to 100°C for about two to ten hours.

 The Formula V compounds wherein R_3 , R_4 and R_1 are as defined above, may be prepared from the appropriate Formula XI compound wherein R_3 and R_4 are as defined above and N-R-R is an appropriate leaving group (e.g., R is alkyl) by
25 condensation/cyclization with the appropriate amine.

 Typically the Formula XI compounds and the appropriate amine are heated at 50°C to 100°C, preferably at reflux, in a suitable solvent such as an alcohol, a chlorinated solvent, or a polar aprotic solvent for about two hours to eight hours.

30 The Formula XI compounds wherein -NRR, R_3 and R_4 are as defined above, may be prepared from the appropriate Formula VII compounds wherein R_3 and R_4 are as defined above and X is an ester that contains a group that is easily displaced (e.g., alkoxy) by condensation with the appropriate formamide acetal.

Typically the Formula VII compound is heated with the formamide acetal at a temperature of 50°C to 150°C in an aprotic solvent such as an aromatic solvent, a hydrocarbon solvent, or a chlorinated solvent with an acid catalyst such as a mineral acid or a sulfonic acid for 2 to 8 hours.

- 5 The Formula VII compounds, wherein R_3 and R_4 are as defined above and X is an ester that contains a group that is easily displaced (e.g., alkoxy), may be prepared from the appropriate Formula VIII compound and consequently the appropriate Formula IX and X compounds in an analogous manner to that described above.

- The starting materials/reagents for the above described reaction schemes (e.g.,
- 10 Formula IX and X compounds, the amines, the alkyl oxalates, the alkyl compounds, $R_5C(O)NH_2$, $R_5C(OR)_3$, formamide acetals or amines) can be easily synthesized by those skilled in the art starting from common chemical reagents using conventional methods of organic synthesis. In addition, the prodrugs claimed herein can be easily synthesized by those skilled in the art using standard methods of organic synthesis and
- 15 in light of the information contained herein. Some of the preparation methods described herein may require protection of remote functionality. The need for these protecting groups will vary depending on the nature of the remote functionality and the conditions of the preparation methods. This need is readily determined by one skilled in the art. For a general description of protecting groups (e.g., halo(C_1 - C_4)alkyl, (C_1 -
- 20 C_4)alkoxymethyl, arylmethyl and tri(C_1 - C_4)alkylsilyl) and their use, see T.W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.

- Some of the compounds of this invention are acidic and can form a salt with a pharmaceutically acceptable cation. Some of the compounds of this invention are basic and can form a salt with a pharmaceutically acceptable anion. All such salts are
- 25 within the scope of this invention and can be prepared by conventional methods. For example, they can be prepared simply by contacting the acidic and basic entities, usually in a stoichiometric ratio, in either an aqueous, non-aqueous or partially aqueous medium, as appropriate. The salts are recovered either by filtration, by precipitation with a non-solvent followed by filtration, by evaporation of the solvent, or, in the case
- 30 of aqueous solutions, by lyophilization, as appropriate.

 The compounds of this invention are all readily adapted to therapeutic use as tyrosine kinase inhibitors for the treatment of tyrosine kinase dependent diseases in mammals (e.g. humans). Tyrosine kinase dependent diseases refer to

hyperproliferative disorders which are initiated/maintained by aberrant tyrosine kinase enzyme activity. Examples of such diseases are cancer, atherosclerosis, antiangiogenesis (e.g., tumor growth, diabetic retinopathy), etc. Exemplary types of cancer include breast, colon and uterine cancer.

- 5 The in vitro tyrosine kinase inhibitory activity of the compounds of this invention may be demonstrated by methods based on standard procedures. In one method the enzyme pp60src, a tyrosine-specific phosphokinase (tyrosine kinase) associated with the inner surface of the plasma membrane, is purified from Rous sarcoma virus-transformed rat cells. In the basic assay the enzyme is incubated with the substrate,
- 10 va15 angiotensin II, and gamma-32p-ATP in a total volume of 25 μ l for 25 minutes at 30°C according to Wong, T.W., Goldberg, A.R. J. Biol. Chem., 259, 8505-8512 (1984). The reaction is terminated by the addition of 45 μ l of 5% TCA, incubated on ice for 5 minutes and centrifuged for 1 minute to remove precipitated protein. 35 μ l aliquots of the supernatants are applied to phosphocellulose paper circles, which are then washed
- 15 in 3 changes of 0.5% H_3PO_4 , acetone-rinsed, dried and counted by liquid scintillation. For screening, the compound to be tested is included in the 25 μ l incubation mixture; compounds are tested at $10^{-4}M$, $10^{-5}M$ and $10^{-6}M$ and appropriate solvent controls are included in all assays.

- The compounds of this invention are administered either orally or parenterally,
- 20 or topically (e.g., eye drops), in dosages ranging from about 0.1 to 10 mg/kg of body weight per day in single or divided doses. In any event the amount and timing of compound(s) administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgment of the prescribing physician. In particular situations, at the discretion of the attending
- 25 physician, doses outside of this range will be used.

Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition (1975).

- 30 The compounds of this invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically-acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, elixirs, syrups, injectable or eye drop solutions, and the like.

Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents.

For purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the essential active ingredient therein can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

For purposes of parenteral administration, solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble, alkali metal or alkaline-earth metal salts previously enumerated. Such aqueous solutions should be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.

For purposes of topical administration, dilute sterile, aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, are prepared.

In a pharmaceutical composition comprising a compound of this invention, or a pharmaceutically-acceptable salt or prodrug thereof, the weight ratio of carrier to active ingredient will normally be in the range from 1:4 to 4:1, and preferably 1:2 to 2:1. However, in any given case, the ratio chosen will depend on such factors as the solubility of the active component, the dosage contemplated and the precise route of administration.

EXAMPLES 1-12

The following 5,10-dihydropyrimido[4,5-b]quinolin-4(1H)-ones were prepared from the corresponding pyrimido[4,5-b]quinolin-4(1H)-ones using an analogous procedure to that described in: Campaigne, E.; Randau, G. J. Het. Chem., 1971, Vol.

5 8, p. 111.

EXAMPLE 1

5,10-Dihydro-7-methoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. >300°C (DMF).

Anal. Calc'd for $C_{12}H_{11}N_3O_2$: C, 62.87; H, 4.84; N, 18.33. Found: C, 62.79; H, 4.67; N, 18.30.

10

EXAMPLE 2

5,10-Dihydro-8-methoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. >300°C (DMF).

Anal. Calc'd for $C_{12}H_{11}N_3O_2$: C, 62.87; H, 4.84; N, 18.33. Found: C, 62.69; H, 4.65; N, 18.25.

EXAMPLE 3

15 5,10-Dihydro-7,8-dimethoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. 303°C dec (DMF).

EXAMPLE 4

5,10-Dihydro-2-ethylpyrimido[4,5-b]quinolin-4(1H)-one; m.p. 281-283°C dec (AcOH/H₂O).

20

EXAMPLE 5

5,10-Dihydro-7,8-dimethoxypyrimido[4,5-b]quinolin-4(1H)-one-2-(N-((3'-morpholino)propyl)carboxamide); m.p. 239-243°C. Anal. Calc'd for $C_{21}H_{27}N_5O_5 \cdot H_2O$: C, 56.62; H, 6.56; N, 15.72. Found: C, 56.40; H, 6.23; N, 15.87.

EXAMPLE 6

25 5,10-Dihydro-7,8-dimethoxy-3-(3'-((N-morpholino))propyl)pyrimido[4,5-b]quinolin-4(1H)-one; m.p. 178-180°C (EtOH/acetone/hexanes). Anal. Calc'd for $C_{20}H_{26}N_4O_4 \cdot 0.5 H_2O$: C, 60.74; H, 6.88; N, 14.17. Found: C, 60.42; H, 6.59; N, 14.00.

EXAMPLE 7

30 5,10-Dihydro-7-thio(4-methoxyphenoxy)pyrimido[4,5-b]quinolin-4(1H)-one; m.p. 280-283°C. Anal. Calc'd for $C_{18}H_{15}N_3O_2S \cdot 0.5 H_2O$: C, 62.42; H, 4.66; N, 12.13. Found: C, 62.79; H, 4.27; N, 12.50.

EXAMPLE 8

5,10-Dihydro-8-ethoxy-7-methoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. 318-320°C. Anal. Calc'd for $C_{14}H_{15}N_3O_3 \cdot 0.25 H_2O$: C, 60.54; H, 5.63; N, 15.13. Found: C, 60.57; H, 5.27; N, 15.15.

EXAMPLE 9

5,10-Dihydro-7-ethoxy-8-methoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. 335-336°C. Anal. Calc'd for $C_{14}H_{15}N_3O_3 \cdot 0.12 H_2O$: C, 61.03; H, 5.58; N, 15.26. Found: C, 60.99; H, 5.27; N, 15.31.

EXAMPLE 10

10 5,10-Dihydro-8-butoxy-7-ethoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. 324-325°C. Anal. Calc'd for $C_{17}H_{21}N_3O_3 \cdot 0.5 H_2O$: C, 62.95; H, 6.84; N, 12.90. Found: C, 62.85; H, 6.45; N, 12.90.

EXAMPLE 11

15 5,1-Dihydro-8,9-dimethoxypyrimido[4,5-b]quinolin-4-(1H)-one; m.p. 261-263°C. Anal. Calc'd for $C_{13}H_{13}N_3O_3 \cdot 0.12 H_2O$: C, 59.71; H, 5.11; N, 16.07. Found: C, 59.72; H, 4.87; N, 16.26.

EXAMPLE 12

20 5,10-Dihydro-6,9-dimethoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. >300°C (DMF/H₂O). Anal. Calc'd for $C_{13}H_{13}N_3O_3$: C, 60.22; H, 5.05; N, 16.21. Found: C, 60.04; H, 4.95; N, 16.23.

EXAMPLE 13

5,10-Dihydro-7,8-dimethoxy-3-methylpyrimido
[4,5-b]quinolin-4(1H)-one

25 To a heated (90°C), stirred solution of 7,8-dimethoxy-4-oxo-3,4,5,10-tetrahydropyrimido[4,5-b]quinoline (0.25 g, 0.96 mmol) and sodium hydroxide (0.05 g, 1.25 mmol) in water (3 mL) was added dimethylsulfate (0.23 mL, 2.4 mmol). After 0.5 hour, the reaction mixture was diluted with water (20 mL), the solids filtered, washed with acetonitrile and dried in vacuo to afford 0.13 g of the title compound; m.p. 225-230°C.

FORMULA VII INTERMEDIATES

30 The following 2-aminoquinoline-3-carboxamide/carboxylate esters were prepared according to analogous procedures to that described in: Campaigne, E.; Randau, G. J. Het. Chem. 1971, Vol. 8, p. 111.

PREPARATION A

2-Amino-6-methoxyquinoline-3-carboxamide; m.p. 232-233°C.

PREPARATION B

Ethyl 2-Amino-7-methoxyquinoline-3-carboxylate; m.p. 151-154°C.

5

PREPARATION C

2-Amino-6,7-dimethoxyquinoline-3-carboxamide; m.p. 275°C (pyridine).

PREPARATION D

Ethyl 2-Amino-6,7-dimethoxyquinoline-3-carboxylate; m.p. 188-189.5°C.

PREPARATION E

10

2-Amino-7,8-dimethoxyquinoline-3-carboxamide; m.p. 218-219°C.

PREPARATION F

2-Amino-6-thio(4-methoxyphenoxy)-3-carboxamide; m.p. 236-239°C.

PREPARATION G

2-Amino-7-butoxy-6-ethoxy-3-carboxamide; m.p. 225°C.

15

PREPARATION H

2-Amino-6-ethoxy-7-methoxy-3-carboxamide; m.p. 263-264°C.

PREPARATION I

2-Amino-7-ethoxy-6-methoxy-3-carboxamide; m.p. 234-235°C.

PREPARATION J

20

2-Amino-5,8-dimethoxy-3-carboxamide; m.p. 263-264°C.

FORMULA XIV INTERMEDIATES

The following pyrimido[4,5-b]quinolin-4(1H)-ones were prepared from the corresponding 2-amino-quinoline-3-carboxamides/carboxylate esters according to an analogous procedure to that described in: Campaigne, E.; Randau, G. J. Het. Chem.

25 1971, Vol. 8, p. 111.

PREPARATION K

7-Methoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. >300°C (DMF). Anal. Calc'd for $C_{12}H_9N_3O_2$: C, 63.43; H, 3.99; N, 18.49. Found: C, 63.09; H, 3.71; N, 18.43.

PREPARATION L

30

7,8-Dimethoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. 311-312°C (AcOH).

PREPARATION M

7-Ethoxy-6-methoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. 330-331°C. Anal. Calc'd for $C_{14}H_{13}N_3O_3 \cdot 1/8 H_2O$: C, 61.48; H, 4.88; N, 15.37. Found: C, 61.58; H, 4.61; N, 15.30.

5

PREPARATION N

6-Ethoxy-7-methoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. 348-349°C. Anal. Calc'd for $C_{14}H_{13}N_3O_3 \cdot 1.8 H_2O$: C, 61.48; H, 4.88; N, 15.37. Found: C, 61.48; H, 4.65; N, 15.48.

PREPARATION O

10

7-Butoxy-6-ethoxypyrimido[4,5-b]quinolin-4(1H)-one; m.p. 280°C (dec).

FORMULA XIV INTERMEDIATES2-Ethylpyrimido[4,5-b]quinolin-4(1H)-one

A slurry of 2-aminoquinoline-3-carboxamide (1.0 g, 5.3 mmol), (Campaigne, E.; Randau, G. J. Het. Chem. 1971, Vol. 8, p. 111) and p-toluenesulfonic acid-
15 monohydrate (50 mg) in triethyl orthopropionate (25 mL) was refluxed for 24 hours. After cooling, the reaction mixture was diluted into diethyl ether (50 mL), the resulting solids filtered and washed with diethyl ether. The solids were recrystallized from formamide to afford 0.14 g of the title compound; m.p. 240-245°C.

FORMULA XIV INTERMEDIATES

20

Ethyl 7,8-dimethoxypyrimido[4,5-b]quinolin-4(1H)-one-2-carboxylate

A slurry of 2-amino-6,7-dimethoxyquinoline-3-carboxamide (1.0 g, 4.2 mmol) in diethyloxylate (25 mL) was heated at 205°C for 3 hours. After cooling, the solids were filtered, dissolved in warm chloroform (100 mL), treated with charcoal and filtered. The filtrate was concentrated in vacuo to afford 0.40 g of the title compound; m.p. 268-
25 269°C.

FORMULA IV INTERMEDIATES7,8-Dimethoxypyrimido[4,5-b]quinolin-4(1H)-one-2-(N-((3'(N-morpholino)propyl)carboxamide)

A stirred slurry of ethyl 7,8-dimethoxypyrimido[4,5-b]quinolin-4(1H)-one-2-
30 carboxylate (1.0 g, 3.0 mmol) and 4-(3-aminopropylmorpholine (0.9 g, 6.0 mmol) in dimethylformamide was refluxed for 2 hours. The reaction mixture was allowed to cool and then diluted into ice water. The resulting solids were filtered, washed with acetonitrile and dried in vacuo to afford 0.8 g of the title compound; m.p. 227-229°C.

FORMULA XI INTERMEDIATESEthyl 2-((dimethylamino)methylimino)-6,7-dimethoxyquinoline-3-carboxylate

A solution of ethyl 2-amino-6,7-dimethoxyquinoline-3-carboxylate (0.5 g, 1.8 mmol), 1,1-dimethoxytri-methylamine (0.5 g, 4.5 mmol) and p-toluenesulfonic acid in toluene (10 mL) was refluxed for 4 hours. The reaction mixture was concentrated in vacuo, dissolved in hot benzene, treated with charcoal, filtered and the filtrate concentrated in vacuo. The solids were recrystallized from hexane to afford 0.4 g of the title compound; m.p. 125-128°C.

10

FORMULA V INTERMEDIATES7,8-Dimethoxy-3-(3'-((N-morpholino))propyl)pyrimido[4,5-b]quinolin-4(1H)-one


A solution of ethyl 2-((dimethylamino)methylimino)-6,7-dimethoxyquinoline-3-carboxylate (1.0 g, 3.0 mmol) and 4-(3-aminopropyl)morpholine (0.9 g, 6.0 mmol) in ethanol (15 mL) was refluxed for 4 hours, the reaction mixture allowed to cool and the resulting solids filtered. Recrystallization afforded 1.0 g of the title compound as a yellow solid; m.p. 258.5-259°C.

It should be understood that the invention is not limited to the particular embodiments described herein, but that various changes and modifications may be made without departing from the spirit and scope of this novel concept as defined by the following claims.

20

CLAIMS

1. A compound of Formula I



Formula I

and their pharmaceutically acceptable salts and prodrugs thereof wherein

- 10 R_1 is H, alkyl(C_1-C_4), formylalkyl(C_1-C_4), alkyl(C_1-C_4)carbonylalkyl(C_1-C_4), carboxyalkyl(C_1-C_4), alkoxy(C_1-C_4)carbonylalkyl(C_1-C_4), carbamoylalkyl(C_1-C_4), mono-N- or di-N,N-alkyl(C_1-C_4)aminocarbonylalkyl(C_1-C_4), formylcarbamoylalkyl(C_1-C_4), alkanoyl(C_1-C_4)carbamoylalkyl(C_1-C_4), alkoxy(C_1-C_4)carbonylcarbamoylalkyl(C_1-C_4), morpholinocarbonylalkyl(C_1-C_4), 1-pyrrolidinylcarbonylalkyl(C_1-C_4), 1-
 15 piperidinylcarbonylalkyl(C_1-C_4), 4-thiomorpholinylcarbonylalkyl(C_1-C_4), 1-piperazinylcarbonylalkyl(C_1-C_4), 4-alkyl(C_1-C_4)-1-piperazinylcarbonylalkyl(C_1-C_4), hydroxyalkyl(C_1-C_4), alkoxy(C_1-C_4)alkyl(C_1-C_4), mono-N- or di-N,N-alkyl(C_1-C_4)aminoalkyl(C_1-C_4), aminoalkyl(C_1-C_4), formylaminoalkyl(C_1-C_4), alkanoyl(C_1-C_4)aminoalkyl(C_1-C_4), alkoxy(C_1-C_4)carbonylaminoalkyl(C_1-C_4), 1-pyrrolidinylalkyl(C_1-C_4),
 20 1-piperidinylalkyl(C_1-C_4), 4-thiomorpholinylalkyl(C_1-C_4), morpholinoalkyl(C_1-C_4), 1-piperazinylalkyl(C_1-C_4) or 4-alkyl(C_1-C_4)-1-piperazinylalkyl(C_1-C_4);

- R_2 is formyl, alkyl(C_1-C_4)carbonyl, carboxy, alkoxy(C_1-C_4)carbonyl, carbamoyl, mono-N- or di-N,N-alkyl(C_1-C_4)aminocarbonyl, formylcarbamoyl, alkanoyl(C_1-C_4)carbamoyl, alkoxy(C_1-C_4)carbonylcarbamoyl, morpholinocarbonyl,
 25 morpholinoalkyl(C_1-C_4)carbamoyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, 4-thiomorpholinylcarbonyl, 1-piperazinylcarbonyl or 4-alkyl(C_1-C_4)-1-piperazinylcarbonyl or such R_2 groups substituted on alkyl(C_1-C_4), or R_2 is H, alkyl(C_1-C_4), hydroxyalkyl(C_1-C_4), alkoxy(C_1-C_4)alkyl(C_1-C_4), mono-N- or di-N,N-alkyl(C_1-C_4)aminoalkyl(C_1-C_4), aminoalkyl(C_1-C_4), formylaminoalkyl(C_1-C_4), alkanoyl(C_1-C_4)aminoalkyl(C_1-C_4), alkoxy(C_1-C_4)
 30 C_4)carbonylaminoalkyl(C_1-C_4), 1-pyrrolidinylalkyl(C_1-C_4), 1-piperidinylalkyl(C_1-C_4), 4-thiomorpholinylalkyl(C_1-C_4), morpholinoalkyl(C_1-C_4), 1-piperazinylalkyl(C_1-C_4) or 4-alkyl(C_1-C_4)-1-piperazinylalkyl(C_1-C_4); and

R_3 and R_4 are each independently H, alkyl(C_1-C_4), perhaloalkyl(C_1-C_4), methoxyphenylthio, alkoxy(C_1-C_6), perhaloalkoxy(C_1-C_6), formyl, alkyl(C_1-C_4)carbonyl, carboxy, alkoxy(C_1-C_4)carbonyl, carbamoyl, mono-N- or di-N,N- alkyl(C_1-C_4)aminocarbonyl, formylcarbamoyl, alkanoyl(C_1-C_4)carbamoyl, alkoxy(C_1-C_4)carbonylcarbamoyl, morpholinocarbonyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, 4-thiomorpholinylcarbonyl, 1-piperazinylcarbonyl, 4-alkyl(C_1-C_4)-1-piperazinylcarbonyl, mono-N- or di-N,N-alkyl(C_1-C_4)amino, amino, formylamino, alkanoyl(C_1-C_4)amino, alkoxy(C_1-C_4)carbonylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-thiomorpholinyl, morpholino, 1-piperazinyl or 4-alkyl(C_1-C_4)-1-piperazinyl;

- 10 with the proviso that R_1 , R_2 , R_3 and R_4 are not all H.
2. A compound as recited in claim 1 wherein
 R_1 is H, methyl or morpholinopropyl;
 R_2 is H or morpholinopropylcarbamoyl;
 R_3 is 7-methoxy; and
- 15 R_4 is 8-methoxy.
3. A compound as recited in claim 1 wherein
 R_1 is H;
 R_2 is alkyl(C_1-C_4);
 R_3 is H or 7-methoxy; and
- 20 R_4 is H or 8-methoxy.
4. A compound as recited in claim 1 wherein R_1 and R_2 are H; and
 R_3 and R_4 are each independently alkoxy(C_1-C_4).
5. A compound as recited in claim 4 wherein R_3 is 7-alkoxy(C_1-C_4) and R_4 is 8-alkoxy(C_1-C_4).
- 25 6. A compound as recited in claim 4 wherein R_3 and R_4 are each independently methoxy.
7. A compound as recited in claim 6 wherein R_3 is 6-methoxy or 8-methoxy and R_4 is 9-methoxy.
8. A compound as recited in claim 1 wherein R_3 is H; and R_4 is alkoxy(C_1-C_4).
- 30 9. A compound as recited in claim 8 wherein R_1 and R_2 are H; and R_4 is 7-methoxy or 8-methoxy.
10. The compound as recited in claim 1 wherein R_1 , R_2 and R_3 are H; and R_4 is 7-((4-methoxyphenyl)thio).

11. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 and a pharmaceutically-acceptable carrier.

12. A method of treating tyrosine kinase dependent diseases which comprises administering to a mammal suffering from a tyrosine kinase dependent disease a
5 tyrosine kinase dependent disease treating amount of a compound of claim 1.

13. The method as recited in claim 12 wherein the disease is cancer, atherosclerosis or antiangiogenesis.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/IB 95/00172

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D471/04 A61K31/505 //(C07D471/04,239:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC:

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 511 792 (ELI LILLY) 4 November 1992 see page 2, line 1 - line 8; claim 1 -----	1,11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "D" document referring to an oral disclosure, use, exhibition or other means
- "E" document published prior to the international filing date but later than the priority date claimed

- "F" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

26 October 1995

Date of mailing of the international search report

07.11.95

Name and mailing address of the ISA
European Patent Office, P.O. Box 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel.: (+31-70) 340-2040, Fax: (+31-65) epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 95/00172

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 12 and 13 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

60

Internal Application No	
-------------------------	--

Internal Application No	
-------------------------	--

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-511792	04-11-92	JP-A- 5117273 US-A- 5223503	14-05-93 29-06-93

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)